EBMT 2020 | NK CAR-based therapies & future perspectives

Tobias Bexte, cand.med., University Hospital Frankfurt, Goethe University, Frankfurt, Germany, gives an outlook on natural killer (NK) chimeric antigen receptor (CAR)-based therapies and what the future may look like. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).